Skip to Content

Prevnar 13 Approval History

FDA Approved: Yes (First approved February 24, 2010)
Brand name: Prevnar 13
Generic name: pneumococcal 13-valent conjugate vaccine
Company: Pfizer Inc.
Treatment for: Pneumococcal Disease Prophylaxis

Prevnar 13 (pneumococcal 13-valent conjugate vaccine) is a vaccine indicated for active immunization against invasive pneumococcal disease.

Development History and FDA Approval Process for Prevnar 13

DateArticle
Jul 12, 2016Approval Pfizer Receives FDA Approval for Prevnar 13 in Adults Age 18 Through 49
Jan 25, 2013Approval Pfizer Receives FDA Approval For The Use Of Prevnar 13 In Vaccine-Naive Children And Adolescents Aged 6 Years Through 17 Years For The Prevention Of Invasive Pneumococcal Disease
Jan  3, 2012Approval FDA Expands Use of Prevnar 13 Vaccine for People Ages 50 and Older
Feb 24, 2010Approval FDA Approves Prevnar 13 Pneumococcal Disease Vaccine
Jan  5, 2010Pfizer Provides U.S. Regulatory Update On Prevnar 13 Vaccine
Aug 12, 2009Wyeth Provides Regulatory Update on Prevnar 13 in the United States
Mar 31, 2009Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide